Publication:
GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC)

Simple item page
dc.contributor.coauthorEminowicz, G.
dc.contributor.coauthorAlexandre, J.
dc.contributor.coauthorSanchez, L. M. M.
dc.contributor.coauthorBraicu, I.
dc.contributor.coauthorMadry, R.
dc.contributor.coauthorFarolfi, A.
dc.contributor.coauthorVulsteke, C.
dc.contributor.coauthorHasegawa, K.
dc.contributor.coauthorWang, J.
dc.contributor.coauthorKim, J.
dc.contributor.coauthorAnanda, S.
dc.contributor.coauthorTan, D. S.
dc.contributor.coauthorCrafton, S.
dc.contributor.coauthorBlack, D.
dc.contributor.coauthorSlomovitz, B. M.
dc.contributor.coauthorOrlowski, R. J.
dc.contributor.coauthorKruger, S. F.
dc.contributor.coauthorYao, L.
dc.contributor.coauthorMonk, B. J.
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorTaşkıran, Çağatay
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2026-08-14T11:20:03Z
dc.date.issued2025
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.versionPublished Version
dc.identifier.ScopusPercentile98
dc.identifier.ScopusQuartileQ1
dc.identifier.WoSPercentile99,2
dc.identifier.WoSQuartileQ1
dc.identifier.doi10.1016/j.annonc.2025.08.1856
dc.identifier.eissn1569-8041
dc.identifier.embargoN/A
dc.identifier.issn0923-7534
dc.identifier.urihttp://doi.org/10.1016/j.annonc.2025.08.1856
dc.identifier.urihttps://hdl.handle.net/20.500.14288/34275
dc.identifier.volume36
dc.identifier.wos001632551600065
dc.keywordsPembrolizumab
dc.keywordsMaintenance therapy
dc.keywordsImmunotherapy
dc.keywordsPhases of clinical research
dc.keywordsRegimen
dc.keywordsChemotherapy
dc.languageeng
dc.publisherElsevier
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofAnnals of Oncology
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectHealth sciences
dc.subjectMedicine
dc.subjectOncology
dc.titleGOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC)
dc.typeMeeting Abstract
dspace.entity.typePublication
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Collections

Publications without Fulltext